Our study is limited by a relatively small sample size; nevertheless it adds important new data about the immune microenvironment of CD30+ cutaneous lymphoproliferative disorders that may be amenable to manipulation via immunotherapy. This evidence concerns the gene TNFRSF8 and lymphoproliferative syndrome.